Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIANT: GPC3-CAR T Cells for ATRT and CNS Rhabdoid Tumors
NCT07513194Phase 1Not yet recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Sep 2026
- Primary completion
- Oct 2029
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BOXR1030 in Atypical teratoid rhabdoid tumor (ATRT) and Atypical Teratoid Rhabdoid Tumor (AT/RT), sponsored by Baylor College of Medicine. Primary endpoint: Dose-Limiting Toxicity at 4 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
BOXR1030
03
Conditions
Atypical teratoid rhabdoid tumor (ATRT)Atypical Teratoid Rhabdoid Tumor (AT/RT)
Beyond the preview
Go deeper on NCT07513194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07513194.